
|Articles|April 10, 2003
Phase III shaping up - Enrollment completed in final CK clinical trial
Irvine, CA-Refractec Inc. has completed patient enrollment for its phase III clinical trial for conductive keratoplasty (CK) as a treatment for presbyopia.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
AAO 2025 Takeaways: Cornea, refractive surgery, and aesthetics redefined
2
AAO 2025 Takeaways: The new era of glaucoma treatment and surgical precision
3
AAO 2025 Takeaways: The next frontier in retinal therapeutics arrives
4
AAO 2025 Takeaways: A new biomechanical paradigm for presbyopia
5

















































.png)


